Aphena Pharma Solutions Inc. announced that it has approved $7 million for company-wide expansion for future growth opportunities to be completed by the end of 2019. Targeted expansion areas include additional manufacturing space, custom blending suites, new liquid blending vessels and an additional high-speed bottling line.
“As Aphena continues our path towards healthcare contract service excellence and innovation, we are committed to investing in our customers’ future and earning our place as their preferred and trusted partner,” said Aphena CEO Shawn Reilley.
The $7 million expansion includes:
- Two additional large pharmaceutical blending suites with separate air handling systems in the company’s manufacturing facility in Maryland
- Two “state of the art” tri-mix blending tanks with counter-rotating sweep and high-shear mixing with vacuum to handle small and large batching for specialty creams, gels and topical products
- A 30,000-square-foot expansion of the Tennessee facility
- An additional high-speed, fully-automated bottling line with serialization in the company’s Tennessee facility to support both over-the-counter (OTC) and prescription products
“These planned expansions at our Maryland and Tennessee facilities will position Aphena to support significant future growth,” said Aphena COO Bob Scott. “We are committed to investing aggressively as needed to ensure that Aphena remains an industry leader in terms of innovation and turnaround time.”
Aphena Pharma Solutions Inc. is an industry-leading organization providing contract packaging and manufacturing solutions for the pharmaceutical, consumer health and medical device markets. With two separate FDA- and DEA-registered sites in the U.S., Aphena handles solid dose, liquids, gels, creams, ointments, foams, suspensions and lotions.